In 2019 Gedeon Richter launched Terrosa®▼ and Thornton and Ross launched Movymia®▼ which are biosimilar versions of teriparatide. Both these biosimilars are the same strength, 20mcg/80 microlitres, as the originator teriparatide Forsteo® with the same licensed indications. However Forsteo® is a disposable pen device whereas the two biosimilar products are available in re-usable pen devices with replaceable cartridges.
The availability of three teriparatide preparations (originator and two biosimilars) in the UK market creates a potential for confusion in the prescribing, dispensing, and administration of these products. This review summarises safety considerations associated with the use of these products.